Shandong Boan Biotechnology Co., Ltd. (06955.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 2.59

From 52W high−83.32%

Volume1.73M

Market capHKD 1.52B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

HKD 2.59

From 52W high

−83.32%

Volume

1.73M

Market cap

HKD 1.52B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

15.3

MomentumView details →

1D Return

−4.88%

YTD Return

−71.35%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−4.88%

YTD Return

−71.35%

1Y Return

−82.57%

RSI (14)

15.3

vs 50D SMA

−41.36%

vs 200D SMA

−62.25%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.02

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

China's National Medical Products Administration Center for Drug Evaluation approved Boan Biotech's investigational new drug application for BA1203, a PD-1/IL-2 antibody cytokine prodrug for treating multiple solid tumors.6d ago

Boan Biotech announced that its investigational drug BA2201, a long-acting bispecific antibody targeting TL1A and IL-23 for inflammatory bowel disease, has had its new drug clinical trial application accepted for review by the Center for Drug Evaluation of China's National Medical Products Administration.25d ago

Similar companies

Innoviva, Inc.INVA Bicara Therapeutics Inc. Common StockBCAX Xeris Biopharma Holdings, Inc.XERS SinoMab BioScience Limited03681.HK Kardigan, Inc.KARD RAPT Therapeutics, Inc.RAPT Find similar companies →

Latest newsMore news →

China's National Medical Products Administration Center for Drug Evaluation approved Boan Biotech's investigational new drug application for BA1203, a PD-1/IL-2 antibody cytokine prodrug for treating multiple solid tumors.6d ago Boan Biotech announced that its investigational drug BA2201, a long-acting bispecific antibody targeting TL1A and IL-23 for inflammatory bowel disease, has had its new drug clinical trial application accepted for review by the Center for Drug Evaluation of China's National Medical Products Administration.25d ago Boan Biotech issued a profit warning, expecting a net loss of RMB 79 million to 89 million for the six months ended June 2026, compared to a profit of RMB 21 million in the same period last year, due to increased R&D expenses from its accelerated innovation strategy.35d ago